Name

Krka

Legal name

KRKA, tovarna zdravil, d.d., Novo mesto

Website

https://krka.biz

Company type

Public

Founded year

1954

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Novo Mesto

HQ country

Slovenia

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Prescription pharmaceuticals: Generic prescription pharmaceuticals covering therapeutic areas including cardiovascular diseases, gastrointestinal disorders, central nervous system diseases, pain, diabetes, cough and cold. Sold through prescription channels across global markets.
2. Non-prescription products: OTC medicines and food supplements available without prescription, marketed under brand names such as Septolete, Nolpaza Control, Nalgesin, Bilobil, Herbion and others
3. Animal health products: Veterinary parasiticides for dogs and cats, including Milprazon and Fypryst. Distributed through veterinary channels
4. CDMO/contract manufacturing services: Contract development and manufacturing services through joint ventures such as the generics JV with Laurus Labs in India

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

Krka develops, produces and markets its own-brand generic medicines across three product lines: prescription pharmaceuticals (Rx) for cardiovascular, gastrointestinal, central nervous system, pain, diabetes and respiratory conditions; non-prescription (OTC) medicines and food supplements under brands such as Septolete, Nolpaza Control, Nalgesin, Bilobil and Herbion; and animal health products such as Milprazon and Fypryst parasiticides for dogs and cats. The company operates a vertically integrated model from API development through finished dosage form production and distributes products through its own subsidiary network in over 50 countries.

Product overview

Krka is a leading generic pharmaceutical company with 70 years of experience offering three core product lines: prescription pharmaceuticals (treatments for cardiovascular diseases, gastrointestinal disorders, central nervous system diseases, pain, diabetes, cough and cold), non-prescription products (OTC medicines), and animal health products (parasiticides for pets). The company operates a vertically integrated business model controlling development, production, and distribution. Krka also provides healthcare professional web applications including KrkaVetExpert (veterinary support), KrkaDepLink (clinical decision support), KrkaGIriskCalc (GI risk assessment), and patient-focused tools like Krka Test Reflux and Krka4anxiety. Notable product brands include Nalgesin (naproxen-based pain relief), Septolete (throat products), Nolpaza Control (acid reflux), Pikovit (vitamins), Fitoval (hair health), Flebaven (venous health), Bilobil (cognitive support), Herbion (herbal cough remedies), and Milprazon (animal parasiticide). The product portfolio spans human pharmaceuticals across 7 therapeutic areas plus animal health, supported by state-of-the-art manufacturing technology including bilayer tablets, prolonged-release systems, and osmotic pump innovations.

Differentiator

Problem solved

Functional benefit

Brands

• Terme Krka: Health spa and hospitality services
• TAD Pharma
• Septolete
• Nolpaza
• Nalgesin
• Herbion
• Bilobil
• Flebaven
• Milprazon
• Pikovit

Products and services

• Prescription Pharmaceuticals High-quality generic prescription pharmaceuticals covering cardiovascular diseases, gastrointestinal disorders, central nervous system diseases, pain, diabetes and cough and cold, sold through prescription channels across more than 50 countries.
• Non-Prescription Products (OTC) Over-the-counter medicines and food supplements available without prescription, marketed under brands such as Septolete, Nolpaza Control, Nalgesin, Nalgesin Forte, Bilobil, Herbion, Flebaven, Pikovit and Fitoval.
• Animal Health Products Veterinary pharmaceutical products including parasiticides for dogs and cats such as Milprazon (milbemycin oxime/praziquantel) and Fypryst, distributed through veterinary practices, pet stores and pharmacies.
• Nalgesin Naproxen-based pain relief medication for headache, back pain, muscle pain, joint pain, migraine, menstrual pain and musculoskeletal pain, available in regular (275 mg) and Forte (550 mg) formulations with 12-hour relief.
• Septolete Throat and oral health product line including various formulations for sore throat relief, sold without prescription in multiple markets.
• Nolpaza Control Non-prescription proton pump inhibitor for short-term treatment of acid reflux and heartburn symptoms, available in multiple markets including Slovenia and across Europe.
• Pikovit Vitamin supplement product line for children and adults covering essential vitamins and minerals.
• Fitoval Hair care supplement product for hair health and growth, formulated with vitamins, minerals and amino acids.
• Flebaven Non-prescription product for venous circulation and treatment of symptoms related to chronic venous insufficiency and varicose veins.
• Bilobil Ginkgo biloba-based supplement supporting cognitive function and peripheral circulation.
• Herbion Herbal-based cough and cold remedy product line sold without prescription.
• Milprazon Animal health parasiticide for dogs combining milbemycin oxime and praziquantel, used for routine worm control and prevention of heartworm and other parasitic infections.
• KrkaVetExpert Veterinary professional web application providing decision support and product information for veterinarians prescribing or dispensing Krka animal health products.

Quantifiable outcome

• 18+ billion tablets and capsules produced annually
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core, regional and supporting.

• Laurus LabscoreStrategic or Co-development Partner · 20 March 2026Strategic diversification through a generics joint venture with Laurus Labs in India. The partnership enables Krka to leverage Laurus Labs' CDMO capabilities and chemistry expertise while expanding generics manufacturing capacity. Motilal Oswal projects 16% compound annual growth in earnings for Laurus Labs over FY2026-2028 partly driven by this JV with Krka.
• Kazakhstan business partnersregionalStrategic or Co-development Partner · 1 April 2025Krka is active in the Kazakh market alongside other Slovenian companies including Iskra, Gorenje and Lek. The company participates in Kazakhstan-Slovenia business forums to strengthen economic cooperation in logistics, energy and IT sectors. Kazakhstan handles 90% of overland Europe-China trade and reported $288 billion GDP.
• International research institutionssupportingTechnology or IntegrationKrka's API R&D and pharmaceutical development departments collaborate with external research institutions in Slovenia and abroad on analytical methods, preclinical research and clinical studies. Miha Plevnik's team works with external research institutions on nuclear magnetic resonance techniques and synthesis route development.
• External clinical research organisationssupportingStrategic or Co-development PartnerKrka's pharmacokinetics and preclinical research teams work with external partners to plan and carry out clinical studies across Europe, Russia, North America and other regions. Cultural differences between regions are factored into study planning and execution.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Aspen Pharmacare: South African-headquartered global generic and specialty pharmaceutical company with operations across emerging markets. Comparable generic Rx and OTC portfolio with similar focus on cardiovascular, CNS, and pain therapeutic areas, plus emerging market distribution model.
• Gedeon Richter: Hungarian-based generic and specialty pharmaceutical company with strong presence in Central and Eastern Europe, CIS, and Western Europe. Highly comparable in geographic footprint (especially CEE/CIS), therapeutic area mix including CNS and women's health, and vertically integrated manufacturing approach.
• Hikma Pharmaceuticals: Jordan-headquartered generic and specialty pharmaceutical company with significant US, MENA, and European operations. Comparable diversified generic portfolio across injectables, generics, and branded products with similar revenue scale and global distribution model.
• Viatris: Formed from the Mylan-Upjohn combination, Viatris is a major global generic and specialty pharmaceutical company with operations in 165+ countries. Highly comparable business model with generic Rx, branded generics, OTC, and biosimilars across similar therapeutic categories.
• Stada Arzneimittel: German-based European generic pharmaceutical company owned by Bain and Cinven. Closely comparable as a European-focused generic manufacturer with branded generics, OTC, and specialty pharmaceuticals across similar therapeutic areas. Similar mid-size scale and European geographic emphasis.
• Teva Pharmaceutical Industries: Global leader in generic pharmaceuticals with broad therapeutic area coverage, specialty medicines, and biosimilars. Directly comparable as a multi-therapeutic generic manufacturer with global distribution and similar pricing pressure dynamics, though significantly larger scale.
• Sandoz: Novartis spin-off and one of the world's largest generic and biosimilar pharmaceutical companies. Direct peer in generic Rx, generic OTC, and biosimilars, with overlapping therapeutic areas in cardiovascular, CNS, and anti-infectives. Comparable vertically integrated manufacturing model.
• Zentiva: European-based generic pharmaceutical company owned by Sanofi. Comparable in generic Rx, OTC, and biosimilars across cardiovascular, pain, and other therapeutic areas, with strong presence in Central and Eastern European markets similar to Krka.

Emerging players

• Alvotech: Iceland-based biosimilar developer and manufacturer. Partially comparable as a vertically integrated biopharmaceutical manufacturer with similar end-markets in generics-adjacent categories, though focused on biosimilars rather than small-molecule generics. Represents the next-generation competitive threat to traditional generic players.

Regional players

• Polpharma: Poland's largest pharmaceutical manufacturer and one of the leading generic producers in Central and Eastern Europe. Comparable in CEE market focus, generic Rx portfolio, and vertically integrated API-to-finished-product manufacturing. Slightly smaller scale with more regional concentration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/krka

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Krka